Depemokimab: a new long-acting anti-IL5 treatment for severe asthma and chronic rhinosinusitis with nasal polyps
{{output}}
Purpose of review: Clinical data are reviewed pertaining to depemokimab, the first extended life anti-IL5 mAb, for treating severe eosinophilic asthma. This molecule was engineered through amino acid modification (YTE mutation) o... ...
